Jan 14, 2025 · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...

Stock Info Webcasts & Presentations. Financials. Individual Investors ... Lilly Reports Fourth-Quarter 2014 Results 1 MB. Financial Workbook (.xls) 476 KB. Financial Workbook (.xlsx) 222 KB. Q3 Earnings Form 10-Q. Earnings Release 222.5 …

Feb 6, 2024 · Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.

Jan 14, 2025 · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024...

6 days ago · INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also ...

Jan 15, 2025 · Eli Lilly and Company ’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales...

Jan 14, 2025 · (RTTNews) - Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast for fiscal 2024 revenues. The company also...

Jan 14, 2025 · Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B.

Feb 6, 2024 · LLY - Free Report) reported fourth-quarter 2023 adjusted earnings per share (“EPS”) of $2.49, which beat the Zacks Consensus Estimate of $2.46 per share. Earnings rose 19% year over year....

Jan 14, 2025 · A Roller Coaster of Stock Performance: Eli Lilly vs. the S&P 500. As of Tuesday’s trading session, Eli Lilly’s year-to-date (YTD) performance has been underwhelming, with a decline of 5.24%. ... The Q4 2024 revenue estimate of $13.5 billion also suggests a robust 45% year-over-year increase, with notable contributions from blockbuster drugs ...